Cardiovascular Risk Reduction in Type 2 Diabetes: Therapeutic Potential of Dapagliflozin
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - New Zealand
doi 10.2147/dmso.s190356
Full Text
Open PDFAbstract
Available in full text
Date
December 1, 2019
Authors
Publisher
Informa UK Limited